✦ LIBER ✦

PMS31 TWO-YEAR LONGITUDINAL STUDY OF PERSISTENCE TO ANTI-TUMOR NECROSIS FACTOR TREATMENT AMONG RHEUMATOID ARTHRITIS PATIENTS

✍ Scribed by B Tang; M Rahman; A Nairn; A Changolkar

Book ID: 118609527
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 70 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)70833-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS45 A TWO-YEAR LONGITUDINAL STUDY OF S

PMS45 A TWO-YEAR LONGITUDINAL STUDY OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

✍ B Tang; MI Rahman; A Nairn; A Changolkar 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

PAR17 A COMPARISION OF THERAPEUTIC PERSI

PAR17 A COMPARISION OF THERAPEUTIC PERSISTENCE AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

✍ B Tang; O Dabbous; BL Meissner; H Thompson; M Rahman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

AO2 THE ASSOCIATION BETWEEN THERAPEUTIC

AO2 THE ASSOCIATION BETWEEN THERAPEUTIC PERSISTENCE AND NON-PHARMACY COST AMONG ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) IN THE TREATMENT OF RHEUMATOID ARTHRITIS

✍ B Tang; H Thompson; BL Meissner; O Dabbous; M Rahman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PMS32 HIGHER OUT-OF-POCKET PHARMACY EXPE

PMS32 HIGHER OUT-OF-POCKET PHARMACY EXPENSE IS ASSOCIATED WITH HIGHER SWITCHING RATES AMONG ANTI-TUMOR NECROSIS FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS

✍ B Tang; A Changolkar; RS McKenzie; CT Piech 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

The comparative one-year performance of

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

✍ Heiberg, Marte Schrumpf ;Koldingsnes, Wenche ;Mikkelsen, Knut ;Rødevand, Erik ;K 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 1 views

PMS69 Tumor Necrosis Factor Blocker Dose

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

✍ M. Bonafede; S.R. Gandra; K.M. Fox; K. Wilson 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB